HomeCompareATHA vs GBDC

ATHA vs GBDC: Dividend Comparison 2026

ATHA yields 29.63% · GBDC yields 11.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.65M in total portfolio value· pulled ahead in Year 4
10 years
ATHA
ATHA
● Live price
29.63%
Share price
$6.75
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$129.6K
Annual income
$16,960.56
Full ATHA calculator →
GBDC
GBDC
● Live price
11.85%
Share price
$12.66
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.78M
Annual income
$16,389,263.41
Full GBDC calculator →

Portfolio growth — ATHA vs GBDC

📍 GBDC pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATHAGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATHA + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATHA pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATHA
Annual income on $10K today (after 15% tax)
$2,518.52/yr
After 10yr DRIP, annual income (after tax)
$14,416.48/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.11/yr
After 10yr DRIP, annual income (after tax)
$13,930,873.90/yr
At 15% tax rate, GBDC beats the other by $13,916,457.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATHA + GBDC for your $10,000?

ATHA: 50%GBDC: 50%
100% GBDC50/50100% ATHA
Portfolio after 10yr
$10.45M
Annual income
$8,203,111.98/yr
Blended yield
78.48%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

ATHA
Analyst Ratings
5
Hold
Consensus: Hold
Price Target
$13.33
+97.5% upside vs current
Range: $3.00 — $33.00
Altman Z
-18.3
Piotroski
1/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.6% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATHA buys
0
GBDC buys
2
PoliticianChamberTickerTypeAmountDate
David P. Joyce🏢 House$GBDC▼ Sell$1,001 - $15,0002023-06-30
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002023-06-19
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-14
David P. Joyce🏢 House$GBDC▼ Sell$15,001 - $50,0002022-07-12
Teresa Leger Fernandez🏢 House$GBDC▼ Sell$15,001 - $50,0002021-01-20
David P. Joyce🏢 House$GBDC▲ Buy$1,001 - $15,0002020-02-25
David P. Joyce🏢 House$GBDC▲ Buy$15,001 - $50,0002019-05-30
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATHAGBDC
Forward yield29.63%11.85%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$129.6K$20.78M
Annual income after 10y$16,960.56$16,389,263.41
Total dividends collected$88.0K$20.36M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy
Analyst price target$13.33$14.00

Year-by-year: ATHA vs GBDC ($10,000, DRIP)

YearATHA PortfolioATHA Income/yrGBDC PortfolioGBDC Income/yrGap
1$13,663$2,962.96$12,490$1,790.28+$1.2KATHA
2$18,403$3,783.44$16,522$3,157.73+$1.9KATHA
3$24,454$4,762.59$23,578$5,898.68+$876.00ATHA
4← crossover$32,080$5,914.49$37,115$11,886.75$5.0KGBDC
5$41,577$7,251.43$66,136$26,423.57$24.6KGBDC
6$53,271$8,783.33$137,257$66,491.44$84.0KGBDC
7$67,517$10,517.46$341,734$194,868.54$274.2KGBDC
8$84,701$12,458.13$1,050,788$685,133.02$966.1KGBDC
9$105,237$14,606.49$4,099,314$2,974,971.01$3.99MGBDC
10$129,564$16,960.56$20,775,530$16,389,263.41$20.65MGBDC

ATHA vs GBDC: Complete Analysis 2026

ATHAStock

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Full ATHA Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this ATHA vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATHA vs SCHDATHA vs JEPIATHA vs OATHA vs KOATHA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.